diarrhea in Extend­ed release study [Outliers]

posted by Researcher101 – Egypt, 2020-09-23 23:53 (1333 d 16:50 ago) – Posting: # 21935
Views: 1,678

Dear All, I'm asking if I have a study on product containing two actives (one IR and the other extended release) and a participant had a diarrhea after Tmax of the IR active and through the Tmax of the XR active. should I exclude the participant from the study? or include him in the XR active statistical calculation and exclude in the IR? :confused:

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
27 visitors (0 registered, 27 guests [including 8 identified bots]).
Forum time: 16:43 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5